Implantable passive blood ultrafiltration device
An implantable, passive blood ultrafiltration device addresses the limitations of current dialysis methods by providing continuous, low-flow filtration of excess fluid and sodium, enhancing patient comfort and clinical stability through natural blood pressure-driven operation.
Patent Information
- Application Number
- PCT/EP2025/085577
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2025-12-04
- Publication Date
- 2026-11-19
AI Technical Summary
Current dialysis techniques for end-stage renal disease, such as hemodialysis and peritoneal dialysis, are cumbersome, require frequent hospital visits, risk infection, and involve complex equipment and procedures, limiting their effectiveness and patient comfort.
An implantable, passive blood ultrafiltration device using a nanoporous semipermeable membrane anchored between a renal artery and urinary tract, which operates under natural blood pressure without external energy, allowing continuous, slow, and autonomous drainage of excess fluid and sodium.
The device provides continuous ultrafiltration of excess water and sodium, reducing the need for frequent dialysis sessions, improving patient comfort and clinical stability, and is suitable for patients with chronic renal failure, resistant hypertension, or heart failure, by maintaining electrolyte balance without requiring external power or complex setups.
Smart Images

Figure EP2025085577_19112026_PF_FP_ABST
Abstract
Description
[0001] Implantable passive blood ultrafiltration device
[0002] technical field
[0003] The invention relates to renal failure.
[0004] Renal insufficiency refers to the inability of the kidneys to properly filter and clean the body's blood.
[0005] Currently, people with kidney failure must undergo replacement therapy: extrarenal purification (dialysis) or kidney transplantation.
[0006] State of the art
[0007] Extracorporeal renal replacement therapy is used in cases of end-stage renal disease (ESRD).
[0008] "Renal insufficiency" refers to the partial or total, transient or permanent, loss of overall kidney function. "Chronic renal insufficiency" refers to the consequence of progressive and irreversible destruction of nephrons, with a decrease in glomerular filtration rate (GFR), assessed by creatinine clearance. In France, the High Authority for Health (HAS) indicates that the GFR is estimated from serum creatinine using the CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration, Levey et al, Ann Intern Med. May 5; 150(9): 604-612. 2009), with the agreed threshold for defining a decrease in GFR being 60 ml / min / 1.73 m². 2Chronic kidney disease progresses slowly over several months or even years, with kidney function declining until it ceases altogether. This state is called "end-stage renal disease" and corresponds to stage 5 of chronic kidney disease progression, with a glomerular filtration rate (GFR) of less than 15 ml / min / 1.73 m². 2 , according to the NFK-KDOKI National Kidney Foundation - Kidney Disease Quality Initiative classification).
[0009] In France, it is estimated that 92,000 people are being treated for end-stage chronic kidney disease, of which approximately 50,000 are receiving treatment through extrarenal purification and approximately 42,000 have received a transplant, with a mortality rate of 10.4%.
[0010] In France, for the year 2022, hypertensive and vascular nephropathies, diabetic nephropathy represented more than half of the cases of treatment of IRCT, 51600 people with stage 5 chronic kidney disease having been treated by dialysis.
[0011] Between 2012 and 2022, the total number of dialysis patients in France increased by 27% (French Agency for Biomedicine, 2022 Annual Report, REIN, French Register of Replacement Therapy).
[0012] It is estimated that kidney diseases affect nearly 850 million people worldwide (Francis et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 20, 473-485 (2024), / 10. 1038 / s41581 -024-00820-6).
[0013] Apart from kidney transplantation, which affects approximately 3,200 patients in France each year, treatment for end-stage renal disease is provided by chronic hemodialysis, using various methods: peritoneal dialysis, hemodialysis (home dialysis, self-dialysis, medically assisted dialysis, and center-based hemodialysis). These treatments affect approximately 11,000 new patients in France each year.
[0014] The term "dialysis" refers to a technique that allows exchanges between two liquids of different compositions, separated by a semi-permeable membrane. The term "chronic hemodialysis" refers to extrarenal purification techniques used to treat chronic kidney failure; these techniques rely on exchanges, across a semi-permeable membrane, between the components of plasma and those of an electrolyte solution called dialysis fluid or dialysate, whose composition is generally close to that of normal extracellular fluid.
[0015] A general overview of hemodialysis technology is presented, for example, in the documents Petitclerc, Hemodialysis: current events and perspectives, ITBM-RBM, 2001; Merlo et al. Hemodialysis generators: state of the French market, ITBM-RBM 28, 150-168, 2007; Sirshendu De et al. Hemodialysis Membranes: for Engineers to Medical Practitioners, ISBN 9780367573737, 230 pages, 2020.
[0016] Three main types of extrarenal purification are used in commercially available dialysis machines: hemodialysis, hemofiltration, and peritoneal dialysis, as well as their variants: hemodiafiltration and biofiltration. Peritoneal dialysis uses the peritoneum as a semi-permeable membrane. The other dialysis techniques employ artificial membranes.
[0017] In peritoneal dialysis, water transfer is osmotic. Peritoneal dialysis offers several advantages. It is almost always performed at home, eliminating fatigue and travel time to a dialysis center. Peritoneal dialysis can be continuous ambulatory, performed during the day, or automated, performed at night. Peritoneal dialysis does not require the use of coagulants and does not require an extracorporeal blood circuit.
[0018] Peritoneal dialysis is not widely used, particularly in France where approximately 6% of patients treated for end-stage chronic renal failure use peritoneal dialysis, a ratio that has remained virtually unchanged since 2012.
[0019] Self-dialysis (or autonomous hemodialysis) is not widely used in France. Self-dialysis centers allow patients living in the same area to group together, with a nurse providing care but intervening only when necessary. Self-dialysis can be assisted, with the patient receiving training in hemodialysis and achieving partial autonomy.
[0020] Medicalized dialysis is carried out in a unit that accommodates patients who cannot or do not want to be cared for at home or in a self-dialysis unit and who require intermittent medical care.
[0021] Most patients carry out their dialysis sessions in a hemodialysis center (in France 82% of new patients, and 56% of hemodialysis patients).
[0022] Three types of transfer can occur across an extrarenal purification machine membrane: migration, convection, and diffusion. These transfer mechanisms are described, for example, by Jungers et al., Chronic Renal Failure: Prevention and Treatment, ISBN 2-257-17556-5, 2004.
[0023] Diffusion (sometimes called conduction) is a passive transfer of solutes without the passage of water, driven by a concentration gradient across a membrane, between the blood compartment to be purified and the dialysate compartment. This passive transfer allows for the removal of urea, creatinine, potassium, and phosphorus. Convection, or ultrafiltration, is an active transfer of water accompanied by solutes, driven by a pressure gradient between the blood compartment and the dialysate compartment. This active transfer allows for the removal of excess water from the patient.
[0024] Furthermore, some molecules contained in the patient's blood can be adsorbed onto the membrane, potentially forming a biofilm on the membrane.
[0025] In hemodialysis, the transfer of molecules is essentially achieved by diffusion, under the effect of a concentration gradient, with water and sodium being eliminated by ultrafiltration.
[0026] In the so-called hemofiltration variant, the transfer of molecules is convective, through a high permeability membrane, and the patient's fluid balance is ensured by injecting into the blood circuit a replacement solution, with a composition close to that of a normal plasma ultrafiltrate.
[0027] In the so-called hemodiafiltration variant, solute transfer is diffusive (for low molecular weight substances) and convective (for high molecular weight solutes), with hemodiafiltration requiring both a dialysate and a replacement solution. As in hemofiltration, the replacement solution must be sterile and pyrogen-free. Both hemofiltration and hemodiafiltration can be performed online.
[0028] Filtration at the hemodialyzer can be forced by increasing the transmembrane pressure (TMP) between the blood compartment and the dialysate compartment. This increase in TMP is achieved by an ultrafiltration controller on the hemodialysis machine. This increase in TMP results in a significant loss of plasma water, which is compensated by the addition of a replacement fluid (stored in external bags or prepared in-line from the dialysate) in predilution and postdilution (Methods and Techniques to Improve the Removal of High Molecular Weight Solutes in Hemodialysis, ITBM-RBM 2001).
[0029] Examples of hemodiafiltration machines can be found in documents US10821216 (Nephros, 2020), EP1351756 (Nephros, 2013), EP2295092 (Bellco, 2011), US6843779 (Mirmedical, 2005), EP692269 (Fresenius, 2000), US5194157 (Sorin, 1993), and US5011607 (Toru, 1991). In hemodialysis, the removal of uremic toxins is achieved through exchanges between plasma and dialysis fluids (dialysate and / or reinfusion fluids) that are free of these toxins. In order to maintain or restore the electrolyte balance of the internal environment, these dialysis fluids must contain the four most quantitatively important cations in the extracellular environment (Na+). + K + , That 2+ , Mg 2+ ) as well as the two quantitatively most important anions (bicarbonate HCO3 - and chloride Cl - ).
[0030] A reduction in dietary sodium intake is recommended for patients with chronic kidney disease, with the expected benefit relating to progression to end-stage renal disease and cardiovascular mortality (Keller et al, Sodium, hypertension, chronic kidney diseases, and public health, Nephrology & Therapeutics, April 2018 pages S93-S98).
[0031] With regard to potassium, renal failure is generally responsible for hyperkalemia (> 5mmol / l), which itself causes cardiac rhythm disorders that are life-threatening (Dussol, Potassium physiology, hypokalaemia and hyperkalaemia, Nephrology & Therapeutics, June 3, 2010, pages 180-199).
[0032] Extrarenal purification (chronic hemodialysis), in its various current forms, presents several disadvantages.
[0033] Peritoneal dialysis remains perceived as risky, particularly with regard to peritoneal infections, or sclerosing and encapsulating peritonitis (see Rottembourg et al, The reality of peritoneal dialysis: 40 years later, Nephro ther, 2018).
[0034] Unlike other hemodialysis techniques, in which an arteriovenous fistula or port is commonly used as vascular access instead of a central venous catheter, peritoneal dialysis requires the use of a catheter. Training for the patient, caregiver, or home health nurse is necessary for catheter exit site care, which is essential to prevent peritoneal infection and maintain aseptic conditions during catheter connections and disconnections. This risk is higher with frequent connections and disconnections, particularly in continuous ambulatory peritoneal dialysis. The risk of infection, which can lead to peritonitis, is increased by age, diabetes, and a high body mass index. Peritoneal infection can cause damage to the peritoneal membrane and even death.
[0035] For peritoneal dialysis, a storage space for dialysate bags and dialysis equipment is required at the patient's home. In addition to the risk of infection, peritoneal dialysis can fail due to catheter malfunction or psychological issues related to accepting the treatment. In France, approximately 50% of patients discontinue peritoneal dialysis within three years.
[0036] Hemodialysis requires three sessions per week, during the day, each usually lasting between 4 and 6 hours. To this session time, the patient must add travel time to and from the treatment center.
[0037] When dialysis is performed in a center, the dialysate is conventionally produced by diluting concentrated solutions. In practice, when dialysis is performed outside the patient's home, in dedicated facilities, the dialysate is continuously produced by a generator during the dialysis session, using ultrapure water and concentrates: most often a bicarbonate concentrate and an acid concentrate. Dialysate production requires complex and expensive equipment.
[0038] Acid concentrate is usually supplied in approximately five-liter containers or in liquid bags. Bicarbonate concentrate is used in conjunction with acid concentrate and is usually supplied in powder cartridges, allowing for the production of buffer for one dialysis session, typically 650g for four hours of dialysis to 1 kg for eight hours of dialysis. The storage and supply of concentrates and cartridges are challenging.
[0039] The manufacture of dialysate from concentrated solutions must comply with detailed regulatory requirements; see in particular European Pharmacopoeia No. 1167: Water for dilution of concentrated solutions for hemodialysis; see also, for example, standard NF S 93-310 of December 2004, relating to the design, operation, performance and safety requirements of water treatment and distribution systems for diluting concentrated solutions for hemodialysis, and standard NF S 93-315 of November 2008, relating to the requirements and recommendations for users of fluids for hemodialysis. Various technical solutions have been proposed in the prior art to try to overcome the drawbacks of chronic replacement hemodialysis techniques.
[0040] For a general presentation of these alternative solutions, one can refer, for example, to the documents Wieringa et al. The Future of Technology-Based Kidney Replacement Therapies: An Update on Portable, Wearable, and Implantable Artificial Kidneys, American Journal of Kidney Diseases, February 2025; Nalesso et al. The Future for End-Stage Kidney Disease Treatment: Implantable Bioartificial Kidney Challenge, Applied Sciences, 2024.
[0041] According to an initial approach, dialysis techniques have been developed to allow the treatment of patients at home with simplified portable equipment, adapted to an extra-hospital environment.
[0042] These techniques use machines that do not generate dialysate from treated water and concentrates, but instead use sterile dialysate, at the final dilution, in a ready-to-use bag. Such simplified machines for home dialysis are known, for example, under the brand names NxStage® and Physidia®.
[0043] The dialysate for NxStage machines is lactate-based and is supplied in five-litre bags, with four to five bags required per dialysis session.
[0044] The dialysate for Physidia® machines is available with a bicarbonate and lactate buffer in five-liter bags. Dialysate bags with bicarbonate buffer have two compartments, requiring pre-mixing before the dialysis session begins, while dialysate bags with lactate buffer are ready to use.
[0045] The use of such portable dialysis machines improves the quality of life of patients suffering from kidney failure, but presents several disadvantages.
[0046] Portable home dialysis machines are expensive. Some of these machines require water treatment for the on-site preparation of dialysate, with complete disinfection of the circuit after each use.
[0047] Patients must have the experience and training necessary to react if they exhibit signs or symptoms of hypertension or hypotension, in the event of excessive or insufficient fluid removal during ultrafiltration.
[0048] According to a second approach, a bioartificial kidney is implanted in the patient's body. Examples include documents US5686289 (Humes, 1997), WO2017 / 096325 (Qidni Labs, 2017), WO2018 / 013947 (Qidni Labs, 2018), and EP4523717 (Shuvo, 2025).
[0049] According to this approach, as indicated in document US5686289, the bioartificial kidney must ensure the purification of nitrogenous waste and hydroelectrolytic homeostasis, and also supplement the non-excretory functions of the kidney, particularly endocrine and immunological functions, through hollow microfibers lined with renal tubular cells.
[0050] Research led by Shuvo Roy (The Kidney Project) resulted in a prototype bioartificial kidney in 2023, combining a hemofilter and a cellular bioreactor that mimic glomerular filtration and tubular function of the kidney. This prototype was tested for a few days in pigs. See, for example, the article by Kim et al., "Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes," Nature Communications, 2023.
[0051] The Kidnew Kidney Implant Development Network Worldwide consortium, launched in 2022 and funded by the European Union, aims to reproduce the glomerulus / tubule tandem of the nephron, by a nanoporous membrane performing blood filtration under normal arterial pressure, and a tubular cell bioreactor applied on a similar membrane, to secrete the remaining waste and reabsorb the useful solutes, resulting in the formation of balanced urine.
[0052] The creation of bioartificial kidneys is very complex, particularly due to the need to prevent immunological and hemorrhagic risks, as well as the need for surgical intervention in the event of an anomaly on one of the components of the bioartificial kidney.
[0053] According to a third approach, portable dialysis systems are offered, such as for example under the name WAK® (wearable artificial kidney), resulting from the work of Victor Gura, a portable device connected to the blood vessels by a catheter, the device regenerating the dialysate.
[0054] Dialysate regeneration remains a critical point under investigation for the implementation of such wearable devices. For example, see the review presented in 2025 by Fabiani et al., "Sorbent-based dialysate regeneration for the wearable artificial kidney: Advancing material innovation via experimental and computational studies," Separation and purification technology, 2025.
[0055] According to a fourth approach, filtration is performed by an implantable system operating continuously.
[0056] US patent 5902336 (Mirimedical, 1999) describes an implantable ultrafiltration device comprising a tubular graft connected to a blood vessel (iliac artery or vein). The graft is equipped with an ultrafiltration membrane. The device includes a pump and tubing connecting the pump outlet to the bladder or ureter. WO2012122240 (Zvi, 2012) describes a continuously operating implantable system that uses blood or arterial pressure. The system comprises an array of semi-permeable nanotubes, for example, made of carbon, placed in a casing fixed as a shunt to a blood vessel such as a vein or artery. The casing is, for example, made of silicone. The nanotubes are arranged parallel to each other and aligned with the blood flow.Blood entering the system is filtered by nanotubes, and impurities are removed in the outflow from the nanotubes via a tubular structure connected to the ureter or directly to the bladder. An electric field is applied to the nanotubes to remove charged impurities. The electrical potentials applied to the implantable system can be modified based on information from sensors measuring, for example, the osmotic pressure or ionic conductivity of the blood. The blood flow rate through the implantable system is determined by the patient's blood flow rate. A microprocessor controls the removal rate of charged species by adjusting the electrical potentials applied across the outer casing containing the semi-permeable nanotubes.The system is presented as an artificial kidney, allowing low-efficiency purification without the application of external pressure; this low efficiency is compensated by continuous operation and multiple passages of blood through the system.
[0057] The invention aims to overcome, at least in part, the drawbacks of the techniques proposed in the prior art. One object of the invention is to provide an implantable, low-flow, passive filtration device allowing slow, continuous and autonomous drainage, without the need for manipulation.
[0058] Another object of the invention is to provide an implantable filtration device enabling the treatment of sodium and water overload (particularly between two dialysis sessions), especially in cardiorenal pathologies, or resistant arterial hypertension, heart failure (particularly congestive), edema refractory to diuretics.
[0059] Another object of the invention is to provide a device fulfilling at least one of the two above objects, the device being implantable via endovascular route, in particular via arterial route.
[0060] Another object of the invention is to provide a device that meets at least one of the above objectives, the device being easy to maintain or replace.
[0061] To this end, a first approach proposes an implantable passive blood ultrafiltration device, comprising a nanoporous semipermeable membrane and anchoring means to the wall of a renal artery and the wall of the adjacent urinary tract. "Ultrafiltration" here refers to the fact that the nanoporous semipermeable membrane allows the passage of a plasma ultrafiltrate while preventing the passage of blood cells and macromolecules.
[0062] "Ultrafiltration" here refers in particular to the fact that the nanoporous semi-permeable membrane retains blood cells and plasma proteins, while allowing water and small solutes, advantageously less than 50 kDa, to diffuse through.
[0063] By "anchoring means" we mean here means enabling the membrane to be hermetically sealed between a lateral wall of a renal artery and a wall of a renal urinary structure, such as a calyx, or the renal pelvis, or a proximal segment of the ureter.
[0064] The calyx refers to the initial intrarenal part of the upper urinary excretory tract, collecting urine from the papilla and draining it towards the renal pelvis.
[0065] Anchoring methods include, for example, a frame, clips, or hooks, or an anchoring stent. Thus, when the device is implanted between a renal artery (or a renal arterial branch) and an intrarenal urinary tract, no direct contact is established between the blood circulating in the artery and the urine present in the urinary tract.
[0066] Advantageously, the anchoring means are of the removable, reversible type.
[0067] In some implementations, the anchoring means include clips, and / or hooks, and / or magnets. Advantageously, the magnets are activated by the approach of a catheter.
[0068] Magnets are advantageously biocompatible, for example of the neodymium-iron-boron type, or samarium cobalt, possibly coated, in particular with gold or titanium nitride or parylene.
[0069] It is therefore possible to atraumatically extract a semipermeable membrane and place a new membrane, or to replace the membrane after cleaning, access to the membrane for its change being carried out via an endoluminal route, for its cleaning or periodic replacement, without total explantation of the device.
[0070] By "passive ultrafiltration device" we mean here that the device does not require and advantageously does not include any external energy source, for example electrical, ultrafiltration being achieved, when the device is implanted, by the patient's natural blood pressure.
[0071] Depending on various implementations, the anchoring means include a shape-memory metal alloy frame, for example nickel-titanium alloy, notably Nitinol®, or a polymer or ceramic material frame, on which the nanoporous semi-permeable membrane is mounted.
[0072] In some implementations, the nanoporous semi-permeable membrane is substantially flat and is made of polymer material or ceramic material.
[0073] In specific applications, the nanoporous semi-permeable membrane is made of a material selected from the group including polycarbonates, polysulfones, and polyethersulfones. Advantageously, the semi-permeable membrane is made of polycarbonate marketed under the name "track-etched," or of hydrophilic polysulfone or polyethersulfone. Advantageously, the thickness of the semi-permeable membrane is a few tens of microns.
[0074] Advantageously, the nanoporous semi-permeable membrane is coated with polyethylene glycol.
[0075] Advantageously, the nanoporous semi-permeable membrane has a cutoff threshold between 30 kDa and 50 kDa. This cutoff threshold prevents the passage of albumin (approximately 66 kDa) and macromolecules such as immunoglobulins, and allows the passage of water and small solutes, such as urea (approximately 60 Da), creatinine (approximately 113 Da), and glucose (approximately 180 Da).
[0076] Advantageously, the nanoporous semi-permeable membrane has pores with a diameter between 5 and 10 nanometers.
[0077] Advantageously, the surface area of the semi-permeable membrane extends over a few square centimeters.
[0078] According to a second aspect, various techniques for implanting a passive blood ultrafiltration device as presented above are proposed.
[0079] In some implementations, the device is implanted endovascularly in the posterosuperior region of the kidney, at the junction between a posterior or superior segmental arterial branch, originating from the renal artery, and the superior calyx. At this location, the superior arterial branches are most often close to the superior calyx, with an anatomical distance that varies from patient to patient, on the order of two millimeters.
[0080] In a first implantation route, called ascending calyceal, the approach is made from the calyx, for example by percutaneous nephrostomy or by urethral route, and mural puncture towards the renal artery, dilation, then insertion of the filtering membrane from the calyx.
[0081] In a second implantation route, known as double mural catheter, two catheters are introduced simultaneously into the artery and the opposite calyx, with creation of a controlled mural pore and insertion of the filtering membrane from the urinary side.
[0082] In a third implantation method, known as robot-assisted, 3D navigation guidance is performed with wall puncture, followed by sealing of the filter membrane using thermal or mechanical systems. In a variant, endowed with superior arterio-calyceal, the implantation is performed between a superior renal artery and a superior calyx, the effect of gravity increasing the efficiency of passive drainage.
[0083] In another variant, called arterio-pyelic, a mural contact is made between the arterial branch and the anterior face of the renal pelvis, allowing a frontal fusion for the placement of the implantable device.
[0084] In another variant, called proximal arterio-urethral, the implantation is made between a renal or accessory artery and the initial portion of the ureter.
[0085] The implantation is advantageously performed under imaging guidance (angiofluoroscopy, urinary endoscopy, ultrasound), allowing for precise alignment of the semipermeable membrane between the artery and the corresponding urinary cavity.
[0086] A third aspect is proposed, a method for implanting a passive blood ultrafiltration device as presented above, the method comprising access to a renal artery via an endovascular route using a carrier catheter, the creation of an opening in the wall of the renal artery, advantageously concomitant access to the urinary cavity via an endourological or percutaneous route, and the positioning of the ultrafiltrating membrane between the artery and the urinary cavity by fixing it hermetically to the edges of said arterial opening and to the wall of the urinary cavity.
[0087] The process advantageously includes the deployment of the anchoring means to hold the semipermeable membrane in place, before removal of the catheters.
[0088] The deployment is advantageously achieved by inflating a balloon applying the semipermeable membrane simultaneously against the arterial wall and the wall of the urinary cavity.
[0089] It is proposed, according to another aspect, the use of an implantable passive blood ultrafiltration device as presented above, for renal replacement in a patient with renal insufficiency, this use advantageously allowing continuous ultrafiltration of the patient's blood in vivo and the elimination of a volume of ultrafiltrate in the urine.
[0090] The term "patient" here refers to both a human and an animal.
[0091] Another option is a kit for implanting a patient's passive blood ultrafiltration device. The kit includes an endovascular implantation module capable of delivering the semipermeable membrane and its anchoring means to a target site and securing it to the arterial wall. The kit also includes a catheter that can be inserted via the urinary tract to secure the semipermeable membrane to the urinary tract wall. The catheter can be inserted retrogradely through the bladder and ureter, or percutaneously antegradely into a calyx.
[0092] According to another aspect, it is proposed to implement an implantable passive blood ultrafiltration device as presented above, the semipermeable membrane being sealed at the level of a fenestration made between the renal artery and the adjacent urinary cavity, the membrane being attached to the wall of the artery and to the wall of the urinary cavity, and forming a fixed interface between these two walls.
[0093] It is proposed, according to another aspect, the implementation of an implantable passive ultrafiltration device for blood as presented above, the device comprising a tubular conduit forming a bypass between the renal artery and the urinary tract, the semipermeable membrane being arranged within this conduit, so as to divide the conduit into a blood compartment, in continuity with the renal artery, and a filtrate compartment in continuity with the urinary tract.
[0094] Advantageously, the conduit is sized to draw only a small flow of blood from the artery and return the unfiltered blood to the main arterial circulation upstream or downstream.
[0095] Other objects and advantages of the invention will become apparent from the description of embodiments given below with reference to the accompanying drawings in which:
[0096] - Figure 1 is a schematic view of the creation of a pore between a renal artery and a urinary tract, for example a calyx or the ureter, before the placement of a semi-permeable filtering membrane;
[0097] - Figure 2 is a view similar to Figure 1, after implantation of an annular fixation frame in the pore made between the renal artery and the urinary tract;
[0098] - Figure 3 is a view of the approach of a semipermeable filter membrane mounted on a frame, this approach being carried out via an endoluminal route, on the side of the urinary tract; - Figure 4 is a view similar to Figure 3, after placement of the semipermeable membrane on the fixation ring;
[0099] Figure 5 is a schematic view showing the placement of a semipermeable membrane using a balloon catheter. The implantable devices that will be described with reference to the attached figures are advantageously introduced and implanted endovascularly.
[0100] Advantageously, the devices are introduced via an arterial route, preferably the femoral artery, without recourse to a vein, up to an intrarenal arterial branch.
[0101] When the device is placed opposite the intrarenal arterial branch, a mural pore is created, for example by radio frequency or laser.
[0102] A stent or patch is then put in place.
[0103] In one implementation, the means of anchoring the semipermeable membrane include a segmental intra-arterial stent, the deployment of which allows the semipermeable membrane to be pressed against the opening made in the arterial wall, this stent occupying only a portion of the perimeter of the artery.
[0104] In some implementations, the means of anchoring the semipermeable membrane include a collar or micro-anchors intended to be fixed to the wall of the calyx.
[0105] In other implementations or in combination, the anchoring means include clips and / or hooks and / or magnets, for example made of neodymium-iron-boron or samarium-cobalt.
[0106] In some implementations, surgical glue is used.
[0107] The devices form a bypass between the renal artery and the urinary cavities of the kidney, allowing continuous drainage of a fraction of the blood plasma into the urinary tract.
[0108] In the embodiment shown schematically in Figures 1 to 4, the implantable device 1 is substantially flat and is interposed between the wall of an artery 2 and that of a calyx 3, and sealed in a precise wall contact. The filter membrane 4 allows continuous ultrafiltration without blood flow.
[0109] Device 1 shown in Figure 4 forms a wall interface, without obstruction of artery 2, device 1 is integrated into the wall of artery 2 itself, the semi-permeable membrane 4 forming a filtering window towards the adjacent urinary tract 3, the lumen of artery 2 remaining free throughout its section, arterial blood flow not being hindered.
[0110] In one implementation, a frame, for example circular or annular, made of biocompatible material, keeps the membrane taut, and fits into an orifice or pore made in the wall of the artery, ensuring the seal on the arterial side.
[0111] In one implementation, a similar frame anchors the semipermeable membrane to an opening or pore made in the urinary-side wall, for example in the wall of the renal pelvis or ureter, ensuring urinary-side sealing.
[0112] When the device is in place, a fixed interface is placed between the renal artery and the urinary tract, without disturbing physiological flows: blood flows freely in the artery, and the urine formed flows freely to the bladder.
[0113] The device shown in Figure 4 forms an arterio-urinary patch, the semipermeable membrane 4 replacing a small area of the arterial wall with a plasma-permeable window.
[0114] The portion of the semipermeable membrane is advantageously positioned parallel to the inner face of artery 2, thus reducing the risks of turbulent flow.
[0115] The portion of the semipermeable membrane fits advantageously against the wall of the calyx so as not to impede the flow of urine.
[0116] In the embodiment shown in figures 1 to 4, the procedure for implanting the device 1 includes a first step of creating a mural pore 6 between a renal artery 2 and a urinary tract such as a calyx or ureter 3 (figure 1).
[0117] In a second step, a fixing ring 5 is placed in the wall pore 6 (figure 2).
[0118] In a third step, a semipermeable membrane 4 mounted on a frame is approached to the fixation ring 5, using a catheter, via the urethral or calicial route (figure 3).
[0119] In a fourth step, the semipermeable membrane 4 is mounted on the fixation ring 5, the ultrafiltrate UF flowing into the calyx or ureter through the semipermeable membrane 4, the formed elements of the blood remaining in the artery 2 (figure 4).
[0120] In the embodiment shown schematically in Figure 5, the implantable device 1 comprises a mural stent 10, equipped with a filter membrane 4, sealed in a mural pore created, for example, by radiofrequency or laser. The lateral filter membrane is advantageously positioned opposite a calyx, and allows continuous ultrafiltration without disrupting blood flow.
[0121] In an implementation of the implantation, in a first step, a pore 6 is made between a renal artery and a calyx or ureter, in a manner similar to what has been described with reference to Figure 1.
[0122] In a second step, a balloon catheter 11 equipped with a stent 10 carrying a semipermeable membrane 4 is introduced arterially at the level of the pore 6.
[0123] In a third step, the semi-permeable membrane is put in place by deploying the balloon.
[0124] In a fourth step, the catheter is detached from the stent, the semipermeable membrane 4 being held in place by the stent, and forming a filtering window between the renal artery and the urinary tract.
[0125] In some implementations, a short conduit is interposed between the renal artery and the urinary tract, with the semipermeable membrane interposed in this short conduit.
[0126] The duct forms an external branch of the artery to the urinary tract, for example to the renal pelvis.
[0127] The conduit is advantageously made of a biocompatible flexible material, for example silicone or polyurethane.
[0128] The external diameter of the conduit is advantageously on the order of a few millimeters.
[0129] One end of the tube is advantageously anastomosed laterally to the renal artery or to a branch of this renal artery. The other end of the tube is implanted in the renal pelvis or in the proximal ureter.
[0130] The semipermeable membrane is placed in the duct and separates a blood compartment (portion of the duct connected to the artery) from a urinary compartment (portion of the duct connected to the ureter).
[0131] The residual blood, concentrated in proteins, cannot cross the semipermeable membrane and is pushed back and reintegrated into the main arterial circulation.
[0132] The placement of such a bypass is advantageous when it is difficult to place a membrane directly between the renal artery and a urinary tract in the patient, for example when the distance between the renal artery and the renal pelvis is too great in a patient.
[0133] In some implementations, the conduit is provided with a flow limiter, for example a calibrated orifice at its connection to the artery, so as to allow only a low blood flow.
[0134] In some implementations, the blood flow in the conduit is less than 5% of the total renal arterial blood flow.
[0135] Advantageously, the conduit is self-sealing in case of rupture.
[0136] In the embodiment of Figure 3, the implantable device comprises a balloon stent, provided with a terminal filter membrane, the stent advantageously comprising a one-way valve to prevent any blood reflux into the calyx.
[0137] The surface of the device, particularly the surface of the semipermeable membrane, is advantageously treated to be antithrombotic, for example by heparin coating or NO donor. The implantable passive blood ultrafiltration device is advantageously placed between a renal artery and a urinary tract.
[0138] In other implementations, the device is placed on an iliac artery, or a femoral artery, for example for the treatment of renal failure refractory to diuretics.
[0139] The devices according to the invention have many advantages. The devices are passive and use only the body's natural hydraulic forces (blood pressures and physiological gradients), without the need for an external energy source, in particular without the need for an electrical power supply.
[0140] The device is advantageously entirely passive and does not include any external or embedded power source, the device advantageously not including expensive components such as micro-sensors, pump, electronic circuits, electronic control unit.
[0141] These devices allow for the creation of a direct and controlled connection between the renal bloodstream and the urinary tract, enabling the slow and continuous discharge of excess fluid and sodium, thus reducing the workload of the kidneys or dialysis machines in volume control. The surface area and permeability of the semi-permeable membrane are advantageously such that the ultrafiltration flow rate obtained is advantageously on the order of 1 to 3 mL per minute on average, for example, on the order of 1.6 mL per minute, or 1 to 3 liters per day, under physiological arterial pressure.
[0142] The volumes of ultrafiltrate generated, on the order of 2 L per day, allow for a substitution for the kidney in a normal state. In a patient with end-stage renal failure and anuria, this flow rate allows for the elimination of a significant amount of water and toxic solutes (urea, creatinine, potassium), improving the balance, without however reaching the filtration efficiency of a healthy kidney.
[0143] The implantable device according to the invention thus allows for adjuvant or alternative therapy to dialysis in patients with advanced chronic renal failure, allowing the interval between two conventional dialysis sessions to be prolonged, or maintaining a patent with minimal purification, while awaiting a transplant.
[0144] The implantable device according to the invention allows for slow, continuous, autonomous, passive drainage of excess hydrosodium, without the need for manipulation, extracorporeal monitoring, or venous access.
[0145] The device operates continuously, without filling and emptying cycles, or valves to open and close.
[0146] The flow rate of ultrafiltrate passing through the semipermeable membrane can vary slightly, depending on the patient's systemic blood pressure, with high blood pressure leading to greater ultrafiltrate production, compensated by higher diuresis.
[0147] The slow flow rate across the membrane limits the risks of hemolysis or platelet activation.
[0148] The devices advantageously do not require venous anastomosis.
[0149] The device does not include any venous return circuit for filtered blood, the ultrafiltrate being evacuated to the urinary tract and the portion of filtered blood remaining in the artery, no arteriovenous shunt being created.
[0150] No part of the device permanently penetrates the skin, the device being contained within the patient's body (intravascular, intraparenchymal, and intraluminal urinary).
[0151] The device creates a communication between an intrarenal arterial branch and an adjacent urinary structure, such as calyx, renal pelvis or ureter, into which is inserted a filtering membrane, hermetically sealed, allowing the selective passage of an ultrafiltrate, without blood transfer.
[0152] Patients' clinical stability is improved, hospitalizations are also reduced, and patients' quality of life is better.
[0153] The implantable device also finds advantageous application in patients with chronic renal failure, not yet terminal.
[0154] Slow and continuous drainage allows for the elimination of excess water and sodium without the need for diuretics. This shortens the duration of dialysis sessions and improves patient tolerance.
[0155] The implantable device allows passive ultrafiltration, at very low flow rates, and finds advantageous application for the reduction of sodium and water overload in patients with resistant hypertension, congestive heart failure, or inter-dialytic overload.
[0156] In dialysis patients, fluid and sodium overload between two dialysis sessions is a major factor in decompensation, which can lead to hemodynamic instability, acute pulmonary edema, and emergency hospitalizations.
[0157] The devices according to the invention allow excess water and sodium to be drained.
[0158] The devices according to the present invention make it possible to improve the quality of life of patients with renal failure, by allowing continuous, passive, low-flow filtration, for the treatment of fluid and sodium overload in cardiorenal pathologies, or in cases of resistant arterial hypertension, or heart failure, and diuretic refractory edema.
[0159] The device according to the invention advantageously does not achieve reabsorption, the ultrafiltrate being excreted as such into the bladder, diuresis being increased and hypotonic, the patient having to balance his water and sodium intake accordingly, supplements of bicarbonates, electrolytes or glucose being able to be administered if necessary.
[0160] A flow rate of 1.6 mL per minute with no tubular reabsorption is equivalent to a clearance of approximately 1.6 mL / minute for urea, a modest but significant value over a period of 24 h. The device advantageously does not include any tissue or biological component such as renal cells, tubular epithelial layer, ultrafiltration being advantageously carried out without biological reabsorption mechanism.
[0161] This lack of reabsorption is inherently detrimental to a healthcare professional. The inventor discovered that by limiting the filtration rate with a semipermeable membrane of low permeability, a balance can be achieved between purification and solute loss. The device creates a controlled connection between an intrarenal arterial branch and an adjacent urinary structure, such as a calyx, renal pelvis, or ureter, into which a hermetically sealed filter membrane is inserted, allowing the selective passage of the urine without blood transfer, advantageously without the passage of blood cells or proteins.
[0162] The filter membrane is advantageously nanoporous, blood-tight, and allows only the passage of the blood. Unlike devices called bioartificial kidneys, the devices according to the present invention are not intended to mimic renal function, nor are they intended to replace the use of dialysis techniques. Bleeding is immediately detected by hematuria and can be treated rapidly, for example, by endovascular embolization.
[0163] The device can be flushed, cleaned or replaced by an endovascular route (e.g. arterial access by catheter), or a calyceal route (e.g. urethroscopy or nephrostomy).
[0164] The device does not require extracorporeal circulation, dialysate, perfusion and operates without a pump or external power.
[0165] The device is advantageously implanted between the renal artery and the urinary excretory cavities (calyx, renal pelvis, ureter), as close as possible to the kidney, avoiding any distant vascular connection, and in particular avoiding the placement of a central venous catheter.
[0166] The implantable device integrates into the artery wall, forming a filtering window into the adjacent urinary tract. The artery lumen remains largely unobstructed throughout its cross-section, as the filtering membrane extends laterally to the artery, thus ensuring unimpeded arterial blood flow.
[0167] In some implementations, a frame, for example circular, biocompatible, for example made of nickel-titanium alloy type Nitinol® or a frame made of polymer material keeps the filter membrane taut and fits into the opening made on the arterial wall, ensuring the sealing and stability of the implanted device, without significant narrowing of the arterial section.
[0168] In some implementations, the frame is compressible.
[0169] In some implementations, a similar fastening device secures the filter membrane to the opening made in the wall of the renal pelvis or ureter, ensuring a watertight seal.
[0170] The installation of the device creates a fixed artery-urine interface, without disturbing physiological flows, with blood circulating freely in the artery and the urine formed flowing freely towards the bladder.
[0171] Advantageously, the filter membrane is provided with a hydrophilic surface treatment, for example of polyethylene glycol PEG type, allowing to limit the binding of proteins.
[0172] Advantageously, regular cleaning of the membrane can be carried out in situ by controlled injection of a rinsing solution and / or by light brushing via a microcatheter inserted temporarily, either arterially or urinarily.
[0173] In other implementations or in combination, the device is provided with reversible attachment means, allowing replacement of the filter membrane.
[0174] In some designs, the membrane support frame includes a release mechanism, equipped, for example, with biocompatible clips or magnets, which is advantageously activated by catheter. This allows for the removal of a worn membrane and the insertion of a new one in the same position. This maintenance procedure is performed under simple local anesthesia on an outpatient basis, ensuring the longevity of the implanted device.
[0175] The device can be put in place by a catheter introduced on the arterial side, and by a catheter introduced through the urinary tract, the deployment of the device being carried out by inflation of a balloon which applies the membrane against both walls simultaneously.
[0176] In some implementations, a device is placed on each of the two kidneys, without laparotomy.
Claims
23 Demands 1. Implantable passive blood ultrafiltration device (1), characterized in that it comprises a nanoporous semi-permeable membrane (4) and means for anchoring to a wall of a renal artery and to the wall of the adjacent urinary tract.
2. Implantable passive blood ultrafiltration device (1) according to claim 1, characterized in that the anchoring means comprise a shape-memory metal alloy frame, or a polymer or ceramic material frame, on which the nanoporous semi-permeable membrane (4) is mounted.
3. Implantable passive blood ultrafiltration device (1) according to claim 1 or 2, characterized in that the nanoporous semi-permeable membrane (4) is substantially flat and is made of polymer material or ceramic material.
4. Implantable passive blood ultrafiltration device (1) according to claim 3, characterized in that the nanoporous semi-permeable membrane (4) is made of a material selected from the group comprising polycarbonates, polysulfones, polyethersulfones.
5. Implantable passive blood ultrafiltration device (1) according to claim 3 or 4, characterized in that the nanoporous semipermeable membrane (4) is coated with polyethylene glycol.
6. Implantable passive blood ultrafiltration device (1) according to any one of claims 1 to 5, characterized in that the nanoporous semipermeable membrane (4) has a cutoff threshold between 30 kDa and 50 kDa.
7. Implantable passive blood ultrafiltration device (1) according to any one of claims 1 to 6, characterized in that the nanoporous semi-permeable membrane (4) has pores with a diameter between 5 and 10 nanometers.
8. Kit for the implantation of a device (1) for passive ultrafiltration of a patient's blood according to any one of claims 1 to 7, characterized in that the kit comprises an endovascular implantation module suitable for delivering the semipermeable membrane (4) and its anchoring means to a target site and fixing it to the arterial wall, the kit comprising a catheter suitable for insertion through the urinary tract and for fixing the semipermeable membrane (4) to the urinary wall.
